AYTU BIOPHARMA, INC short interest in 2021
In 2021, AYTU BIOPHARMA, INC's disclosed short interest ran from 1.90% of shares outstanding on 12 Feb 2021 to 5.41% on 31 Dec 2021, a change of +3.51 percentage points. The year's high was 11.62% on 30 Apr 2021 and its low 1.90% on 12 Feb 2021, averaging 7.15% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.97 days on 29 Oct 2021. Full history: AYTU BIOPHARMA, INC.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 1.90% (12 Feb 2021)
- End of year
- 5.41% (31 Dec 2021)
- Change
- +3.51 pp
- High
- 11.62% (30 Apr 2021)
- Low
- 1.90% (12 Feb 2021)
- Average
- 7.15%
- Highest days to cover
- 7.97 (29 Oct 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Feb 2021 | 1.90% | 1.00 | 10-Q filed, results (8-K) |
| 26 Feb 2021 | 2.08% | 1.00 | |
| 15 Mar 2021 | 3.34% | 1.00 | |
| 31 Mar 2021 | 8.29% | 1.26 | |
| 15 Apr 2021 | 10.34% | 4.16 | |
| 30 Apr 2021 | 11.62% | 7.41 | |
| 14 May 2021 | 9.23% | 4.59 | |
| 28 May 2021 | 9.90% | 6.67 | 10-Q filed, results (8-K) |
| 15 Jun 2021 | 10.18% | 1.75 | |
| 30 Jun 2021 | 6.37% | 1.00 | |
| 15 Jul 2021 | 7.76% | 3.16 | |
| 30 Jul 2021 | 8.75% | 5.19 | |
| 13 Aug 2021 | 7.98% | 5.58 | |
| 31 Aug 2021 | 7.50% | 5.93 | |
| 15 Sep 2021 | 8.12% | 5.45 | |
| 30 Sep 2021 | 7.74% | 4.01 | results (8-K), 10-K filed |
| 15 Oct 2021 | 5.33% | 7.74 | |
| 29 Oct 2021 | 7.01% | 7.97 | |
| 15 Nov 2021 | 5.76% | 4.40 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 6.25% | 3.04 | |
| 15 Dec 2021 | 6.35% | 1.78 | |
| 31 Dec 2021 | 5.41% | 2.70 |
See also: AYTU BIOPHARMA, INC's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.